in the absence of a submission from the holder of the marketing authorisation:
rozanolixizumab (Rystiggo®) is not recommended for use within NHSScotland.
Indication under review: as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
The holder of the marketing authorisation has indicated that they plan to make a submission to SMC in the future.
Download detailed advice234KB (PDF)
Medicine details
- Medicine name:
- rozanolixizumab (Rystiggo)
- SMC ID:
- SMC2761
- Indication:
As an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive
- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Central nervous system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 13 January 2025